Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by cigar1on Mar 19, 2011 11:17am
401 Views
Post# 18310130

Short Position Now "0"

Short Position Now "0"
Current Short Interest Shares 0.00
Current Short Interest Ratio 0.00
Float
Short Interest as % of Float
Average Daily Volume 4.77 M
Outstanding Shares 205.35 M
  • Previous 12 Months Short Interest: QEI

    Data as of 03/16/11
      Date Ratio Shares
    Mar 03/16/11 0.00 0.00
    Mar 03/01/11 0.10 284,500.00
    Feb 02/16/11 0.00 68,000.00
    Feb 02/01/11 0.10 494,500.00
    Jan 01/17/11 0.50 2.24 M
    Jan 01/04/11 1.10 4.79 M
    Dec 12/16/10 0.40 1.63 M
    Dec 12/01/10 0.50 1.48 M
    Nov 11/16/10 0.80 2.40 M
    Nov 11/01/10 1.00 2.70 M
    Oct 10/18/10 1.70 3.55 M
    Oct 10/01/10 0.80 1.23 M
    Sep 09/16/10 0.20 209,500.00
    Sep 09/01/10 0.20 339,500.00
    Aug 08/16/10 0.10 178,980.00
    Aug 08/03/10 0.10 134,280.00
    Jul 07/16/10 0.60 359,180.00
    Jul 07/02/10 0.50 314,680.00
    Jun 06/16/10 0.20 183,900.00
    Jun 06/01/10 0.20 429,500.00
    May 05/17/10 0.20 365,000.00
    May 05/03/10 0.10 253,000.00
    Apr 04/16/10 0.10 87,000.00
    Apr 04/01/10 0.10 87,000.00
    Mar 03/16/10 0.00 0.00
    Mar 03/01/10 2.50 2.71 M
Bullboard Posts